Yahoo Canada Web Search

Search results

1. • $2.21

     • Vera Therapeutics has generated ($2.21) earnings per share over the last year (($2.21) diluted earnings per share). Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.57) to ($2.85) per share.
     www.marketbeat.com/stocks/NASDAQ/VERA/earnings/

     Vera Therapeutics (VERA) Earnings Date and Reports 2024

2. People also ask

   How much does Vera Therapeutics make?

   • Vera Therapeutics (NASDAQ:VERA) has a market capitalization of $214.64 million. The company earns $-32,610,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. How can I contact Vera Therapeutics?

   VERA Stock Forecast, Price & News (Vera Therapeutics) - MarketBeat

   www.marketbeat.com/stocks/NASDAQ/VERA/

   See all results for this question

   What are Vera Therapeutics' share price objectives?

   • 4 analysts have issued twelve-month price objectives for Vera Therapeutics' shares. Their VERA share price forecasts range from $6.00 to $38.00. On average, they predict the company's stock price to reach $15.75 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price.

   VERA Stock Forecast, Price & News (Vera Therapeutics) - MarketBeat

   www.marketbeat.com/stocks/NASDAQ/VERA/

   See all results for this question

   Where can I buy Vera Therapeutics stock?

   • Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vera Therapeutics' stock price today?

   VERA Stock Forecast, Price & News (Vera Therapeutics) - MarketBeat

   www.marketbeat.com/stocks/NASDAQ/VERA/

   See all results for this question

   Who founded Vera Therapeutics Inc?

   • Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. It was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA. Vera Therapeutics, Inc. | Complete Vera Therapeutics Inc. stock news by MarketWatch.

   VERA Stock Price | Vera Therapeutics Inc. Stock Quote (U.S.: Nasdaq

   www.marketwatch.com/investing/stock/vera

   See all results for this question

   How many research reports have been made about Vera Therapeutics?

   • Vera Therapeutics has only been the subject of 3 research reports in the past 90 days. Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States.

   VERA Stock Forecast, Price & News (Vera Therapeutics) - MarketBeat

   www.marketbeat.com/stocks/NASDAQ/VERA/

   See all results for this question

   Does Vera Therapeutics offer inducement Awards?

   • BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a...

   Vera Therapeutics, Inc. (VERA) Stock Price, Quote & News - Stock Analysis

   stockanalysis.com/stocks/vera/

   See all results for this question

3. finance.yahoo.com › quote › VERAVera Therapeutics, Inc. (VERA) Stock Price, News, Quote ...

   finance.yahoo.com › quote › VERA

   • Cached

   Find the latest Vera Therapeutics, Inc. (VERA) stock quote, history, news and other vital information to help you with your stock trading and investing.

   • Analysis

     See Vera Therapeutics, Inc. (VERA) stock analyst estimates,...

   • Financials

     Get the detailed quarterly/annual income statement for Vera...

   • Holders

     Holder Shares Date Reported % Out Value; Price (T.Rowe) New...

   • News

     The latest news and headlines from Yahoo News. Get breaking...

4. www.google.com › finance › quoteVera Therapeutics Inc (VERA) Stock Price & News - Google Finance

   www.google.com › finance › quote

   • Cached

   Get the latest Vera Therapeutics Inc (VERA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

5. stockanalysis.com › stocks › veraVera Therapeutics, Inc. (VERA) Stock Price, Quote & News ...

   stockanalysis.com › stocks › vera

   • Cached

   Get a real-time Vera Therapeutics, Inc. (VERA) stock price quote with breaking news, financials, statistics, charts and more.

   • EPS (ttm): 2.22
   • Net Income (ttm): 107.85M

   • Market Cap: 2.26B
   • Shares Out: 54.83M

6. www.marketbeat.com › stocks › NASDAQVera Therapeutics (VERA) Stock Price, News & Analysis

   www.marketbeat.com › stocks › NASDAQ

   • Cached

   4 days ago · Vera Therapeutics, Inc. (NASDAQ:VERA) announced its earnings results on Thursday, August, 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.06.

   • 2/5
   • Email: ir@veratx.com

   • Phone: (844) 978-6257
   • Employees: 40

7. www.investors.com › news › technologyVera Therapeutics Breaks Out On Promising Results For Kidney Drug

   www.investors.com › news › technology

   4 days ago · This causes swelling that can make it difficult for the kidneys to filter waste from the blood. But, over 96 weeks, patients who received Vera Therapeutics ' ( VERA ) treatment showed a 52% ...

8. www.marketwatch.com › investing › stockVERA Stock Price | Vera Therapeutics Inc. Stock Quote (U.S ...

   www.marketwatch.com › investing › stock

   Oct 17, 2024 · VERA | Complete Vera Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

9. www.wsj.com › market-data › quotesVera Therapeutics Inc. (VERA) Stock Price Today - WSJ

   www.wsj.com › market-data › quotes

   • Cached

   View the latest Vera Therapeutics Inc. (VERA) stock price, news, historical charts, analyst ratings and financial information from WSJ.